SORT1 and colorectal carcinoma: In the context of personalized cancer therapy, monitoring sortilin expression could constitute a promising approach to (a) more accurately classify patients, in addition with other criteria, for improving the patient taking in care and to (b) explain 5‐FU resistance in CRC, for improving the knowledge of its mechanism.